Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 18/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28077679 | 0.79 | LMNA (0.49) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5015600 | 0.74 | PRF1 (0.55) | PRF1LMNAGAAMAPTACHE | |
| SCHEMBL12633607 | 0.72 | PRF1 (0.57) | PRF1LMNAGAAMAPTACHE | |
| SCHEMBL19966686 | 0.72 | PRF1 (0.61) | PRF1LMNAGAAMAPTACHE | |
| SCHEMBL13469961 | 0.72 | PRF1 (0.65) | PRF1LMNAGAAMAPTACHE | |
| SCHEMBL19607528 | 0.71 | PRF1 (0.59) | PRF1LMNAGAAMAPTACHE | |
| SCHEMBL12633609 | 0.70 | PRF1 (0.57) | PRF1LMNAGAAMAPTACHE | |
| SCHEMBL16573996 | 0.69 | PRF1 (0.61) | PRF1LMNAGAAMAPTACHE | |
| SCHEMBL12633608 | 0.69 | PRF1 (0.56) | PRF1LMNAGAAMAPTACHE | |
| SCHEMBL19685741 | 0.68 | PRF1 (0.55) | PRF1LMNAGAAMAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1700851-B1 | CRYSTALLINE CITALOPRAM DIOL INTERMEDIATE ALKALI | HANGZHOU MINSHENG PHARM CO LTD (CN) | 2012-09-12 | — | — | EP | disclosed |
| US-7435838-B2 | Crystalline citalopram diol intermediate alkali | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD. (CN) | 2008-10-14 | — | — | US | disclosed |
| US-20070117992-A1 | Crystalline citalopram diol intermediate alkali | ZHEJIANG HONGGUAN BIO-PHARMA CO., LTD. (CN) | 2007-05-24 | — | — | US | disclosed |
| EP-1700851-A1 | CRYSTALLINE CITALOPRAM DIOL INTERMEDIATE ALKALI | Hangzhou Minsheng Pharm. Co., Ltd. (CN) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117992-A1 | Crystalline citalopram diol intermediate alkali | HTR5A, HTR4, HTR3D | PRF1 4870/4885LMNA 912/4885GAA 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.